Simultaneous administration of Ibr and IM was superior in reducing the clonogenic potential of CML-CP patient-derived MNCs and primitive CD34+ cells compared to single TKI application. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.